Luye Pharma provide customers with high-quality medications and professional services by leveraging Luye Pharma’s global R&D capabilities, global manufacturing facilities and global marketing networks.More
With over 30 healthcare facilities in Australia and Asia,Luye Medical is committed to provide patient-centred, value-based integrated healthcare services.More
Through real-time fluorescent qPCR and next-generation sequencing (NGS) technologies in combination with data platforms, Luye Diagnostics provides clinical, intelligent, complete solutions in different stages of the disease.More
Treatment of Recurrent Glioblastoma
Over One Thousand Psychiatrists Gather to Discuss the Diagnosis and Treatment of Mental Disorders During COVID-19
Bringing new treatment option to patients.
The third biosimilar of Avastin® to enter the market in China
The results showed that the novel GalNAc moieties are more convenient and affordable.Compared with the traditional GalNAc.
The research demonstrates that LY-CovMab exhibits excellent neutralization potency against pseudovirus and authentic virus infection.
Brings Increased Clinical Benefits to Schizophrenia Patients through World-leading Microsphere Technology
Comprehensively Improving Symptoms of Depression with Triple Reuptake Inhibitor Profile
Demonstrating Strength of Luye Pharma’s World-Leading Microspheres Technology Platform
The study has provided guidance to clinical medication for the treatment of advanced squamous cell lung carcinoma.
LY03005 is an exclusive CNS product developed under Luye Pharma’s New Chemical and Therapeutic Entities (NCE/NTE) R&D platform.
This regional initiative aims to raise mental health awareness, supporting patients, physicians and health systems in overcoming the unmet needs, especially during the COVID-19 pan...